Daliresp is prescribed for the treatment of chronic obstructive pulmonary disease (COPD) in people age 18 and older. Specifically, this medication is used to prevent exacerbations in people with severe COPD. It is thought that this medicine has anti-inflammatory effects, although it is not exactly clear how it works. There are currently no "off-label," or unapproved, uses for Daliresp.
Daliresp™ (roflumilast) is a prescription medication used to treat chronic obstructive pulmonary disease, which is more commonly known as COPD. It is the first phosphodiesterase type-4 (PDE4) inhibitor medication approved for use in the United States. Unlike most COPD medications that come as inhalers, Daliresp is an oral tablet.
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease in which the lungs are damaged, making it difficult to breathe. In COPD, the airways (the tubes that carry air into and out of your lungs) are partly obstructed, making it difficult to get air in and out. Emphysema and chronic bronchitis are two kinds of COPD. While smoking is the most common cause of this lung disease, there are other possible causes of COPD.
Common COPD symptoms may include:
- Wheezing (a whistling or squeaky sound when you breathe)
- Sputum (mucus) production
- Shortness of breath, especially with exercise
- Chest tightness.
Depending on the severity of your COPD, you healthcare provider may recommend a number of medications as part of your COPD treatment, including:
- Bronchodilators, including short-acting and long-acting bronchodilators
- Steroids, such as inhaled steroids
- A PDE4 inhibitor, such as Daliresp
- A yearly flu shot
- A pneumococcal vaccine.
Daliresp is specifically approved to prevent exacerbations in people with severe COPD associated with chronic bronchitis and a history of exacerbations.